4
Changes in Ownership
BioXcel Therapeutics, Inc. Filed Acc 0001104659-22-128367
CEO and President sold 60,000 shares at an average $19.69 ($1,181,498)
- CEO and President acquired 60,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Mehta Vimal · CEO and President
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2022-12-15 | Exercise or conversion : show line 1 in the form | +30,000 | $0.41 | $12,300 | 39,957 | D |
| 2022-12-15 | Sale : show line 2 in the form | −22,794 | $19.86 | $452,689 | 17,163 | D |
| 2022-12-15 | Sale : show line 3 in the form | −7,206 | $20.19 | $145,489 | 9,957 | D |
| 2022-12-16 | Exercise or conversion : show line 4 in the form | +30,000 | $0.41 | $12,300 | 39,957 | D |
| 2022-12-16 | Sale : show line 5 in the form | −20,113 | $19.21 | $386,371 | 19,844 | D |
| 2022-12-16 | Sale : show line 6 in the form | −9,887 | $19.92 | $196,949 | 9,957 | D |
| Open-market sales · 60,000 sh · avg $19.69 · $1,181,498 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2022-12-15 | Exercise or conversion : show line 7 in the form Stock Option (Right to Buy) | −30,000 | 444,000 | D |
| 2022-12-16 | Exercise or conversion : show line 8 in the form Stock Option (Right to Buy) | −30,000 | 414,000 | D |
Loading xslF345X03/tm2233011-1_4seq1.xml…